- Home
- NPCT vs FHTX Comparison
NPCT vs FHTX Comparison
Compare NPCT & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NPCT
- FHTX
- Stock Information
- Founded
- NPCT 2020
- FHTX 2015
- Country
- NPCT United States
- FHTX United States
- Employees
- NPCT N/A
- FHTX 112
- Industry
- NPCT Investment Managers
- FHTX Medicinal Chemicals and Botanical Products
- Sector
- NPCT Finance
- FHTX Health Care
- Exchange
- NPCT Nasdaq
- FHTX Nasdaq
- Market Cap
- NPCT 316.6M
- FHTX 271.5M
- IPO Year
- NPCT N/A
- FHTX 2020
- Fundamental
- Price
- NPCT $11.18
- FHTX $4.94
- Analyst Decision
- NPCT
- FHTX Strong Buy
- Analyst Count
- NPCT 0
- FHTX 8
- Target Price
- NPCT N/A
- FHTX $12.63
- AVG Volume (30 Days)
- NPCT 107.1K
- FHTX 139.1K
- Earning Date
- NPCT 01-01-0001
- FHTX 08-07-2025
- Dividend Yield
- NPCT 9.82%
- FHTX N/A
- EPS Growth
- NPCT N/A
- FHTX N/A
- EPS
- NPCT N/A
- FHTX N/A
- Revenue
- NPCT N/A
- FHTX $23,504,000.00
- Revenue This Year
- NPCT N/A
- FHTX $44.01
- Revenue Next Year
- NPCT N/A
- FHTX $9.45
- P/E Ratio
- NPCT N/A
- FHTX N/A
- Revenue Growth
- NPCT N/A
- FHTX N/A
- 52 Week Low
- NPCT $8.58
- FHTX $2.95
- 52 Week High
- NPCT $10.63
- FHTX $10.25
- Technical
- Relative Strength Index (RSI)
- NPCT 67.42
- FHTX 57.60
- Support Level
- NPCT $11.15
- FHTX $4.78
- Resistance Level
- NPCT $11.29
- FHTX $5.18
- Average True Range (ATR)
- NPCT 0.11
- FHTX 0.28
- MACD
- NPCT 0.01
- FHTX -0.00
- Stochastic Oscillator
- NPCT 78.69
- FHTX 58.33
About NPCT Nuveen Core Plus Impact Fund of Beneficial Interest
Nuveen Core Plus Impact Fund is an organized, diversified, closed-end management investment company. The Fund's investment objective is to seek total return through high current income and capital appreciation, while giving special consideration to certain impact and environmental, social and governance criteria.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.